Riset dan Pengabdian Masyarakat
Do Research Sosial Service and Innovation
Publikasi Scopus 2024 per tanggal 31 Maret 2024 (233 artikel)
Publikasi Scopus 2024 per tanggal 31 Maret 2024 (233 artikel)
Commons, Robert J (55153877700); Rajasekhar, Megha (57215545833); Edler, Peta (58608629200); Abreha, Tesfay (14031097700); Awab, Ghulam R (36016082300); Baird, J Kevin (15921267800); Barber, Bridget E (36561132900); Chu, Cindy S (57207278580); Cui, Liwang (57307838700); Daher, André (55411631100); Gonzalez-Ceron, Lilia (55989733200); Grigg, Matthew J (55507854900); Hwang, Jimee (35067936600); Karunajeewa, Harin (6602655545); Lacerda, Marcus V G (8836255900); Ladeia-Andrade, Simone (14025832100);
Effect of primaquine dose on the risk of recurrence in patients with uncomplicated Plasmodium vivax: a systematic review and individual patient data meta-analysis
2024
The Lancet Infectious Diseases
24
2
172
183
11
4
https://www.scopus.com/inward/record.uri?eid=2-s2.0-85173156283&doi=10.1016%2fS1473-3099%2823%2900430-9&partnerID=40&md5=96c96e907027eb1c171780ca42f41546
Global Health Division, Menzies School of Health Research and Charles Darwin University, Darwin, NT, Australia; WorldWide Antimalarial Resistance Network (WWARN), Asia-Pacific Regional Centre, Melbourne, VIC, Australia; General and Subspecialty Medicine, Grampians Health—Ballarat, Ballarat, VIC, Australia; Centre for Epidemiology and Biostatistics, Melbourne School of Population and Global Health, The University of Melbourne, Melbourne, VIC, Australia; Department of Medical Biology, The University of Melbourne, Melbourne, VIC, Australia; Department of Infectious Diseases, The University of Melbourne at the Peter Doherty Institute for Infection and Immunity, Melbourne, VIC, Australia; ICAP, Columbia University Mailman School of Public Health, Addis Ababa, Ethiopia; Mahidol Oxford Tropical Medicine Research Unit (MORU), Faculty of Tropical Medicine, Mahidol University, Bangkok, Thailand; Mahidol Vivax Research Unit, Faculty of Tropical Medicine, Mahidol University, Bangkok, Thailand; Department of Clinical Tropical Medicine, Faculty of Tropical Medicine, Mahidol University, Bangkok, Thailand; Nangarhar Medical Faculty, Nangarhar University, Jalalabad, Afghanistan; Oxford University Clinical Research Unit Indonesia, Faculty of Medicine Universitas Indonesia, Jakarta, Indonesia; Centre for Tropical Medicine and Global Health, Nuffield Department of Medicine, University of Oxford, Oxford, United Kingdom; QIMR Berghofer Medical Research Institute, Brisbane, QLD, Australia; Infectious Diseases Society Sabah-Menzies School of Health Research Clinical Research Unit, Kota Kinabalu, Malaysia; Shoklo Malaria Research Unit, MORU, Faculty of Tropical Medicine, Mahidol University, Mae Sot, Thailand; Department of Internal Medicine, Morsani College of Medicine, University of South Florida, Tampa, FL, United States; Fiocruz Clinical Research Platform and Vice‑presidency of Research and Biological Collections, Oswaldo Cruz Foundation (Fiocruz), Rio de Janeiro, Brazil; Laboratory of Parasitic Diseases, Oswaldo Cruz Foundation (Fiocruz), Rio de Janeiro, Brazil; Regional Centre for Public Health Research, National Institute for Public Health, Tapachula, Mexico; US President's Malaria Initiative, Malaria Branch, US Centers for Disease Control and Prevention, Atlanta, GA, United States; Institute for Global Health Sciences, University of California San Francisco, San Francisco, CA, United States; Department of Medicine-Western Health, Melbourne Medical School, The University of Melbourne, St Albans, VIC, Australia; Fundação de Medicina Tropical Dr Heitor Vieira Dourado, Manaus, Brazil; Instituto Leônidas e Maria Deane, Fiocruz, Manaus, Brazil; University of Texas Medical Branch, Galveston, TX, United States; Global Health and Tropical Medicine, Institute of Hygiene and Tropical Medicine, NOVA University of Lisbon, Lisbon, Portugal; Department of Pharmacology and Therapy, Faculty of Medicine and Veterinary Medicine, Universitas Nusa Cendana, Kupang, Indonesia; Unit of Leishmaniasis and Malaria, Instituto de Medicina Tropical Alexander von Humboldt, Universidad Peruana Cayetano Heredia, Lima, Peru; Population Health and Immunity Division, Walter and Eliza Hall Institute of Medical Research, Melbourne, VIC, Australia; Centro de Pesquisa em Medicina Tropical de Rondônia (CEPEM), Porto Velho, Brazil; Fundação Universidade Federal de Rondônia (UNIR), Porto Velho, Brazil; Department of Pediatrics, Medical Faculty, Universitas Sumatera Utara, Medan, Indonesia; Central Department of Microbiology, Tribhuvan University, Kirtipur, Nepal; Department of Parasitology, Faculty of Medicine, University of Indonesia, Jakarta, Indonesia; National Institute of Malariology, Parasitology and Entomology, Hanoi, Viet Nam; Federal University of Pará (Universidade Federal do Pará - UFPA), Belém, Brazil; Oxford University Clinical Research Unit, Hospital for Tropical Diseases, Ho Chi Minh City, Viet Nam; WWARN, Oxford, United Kingdom; Grupo Malaria, Facultad de Medicina, Universidad de Antioquia, Medellín, Colombia; Facultad Nacional de Salud Publica, Universidad de Antioquia, Medellín, Colombia; Infectious Diseases Data Observatory (IDDO), Oxford, United Kingdom
Background: Primaquine is used to eliminate Plasmodium vivax hypnozoites, but its optimal dosing regimen remains unclear. We undertook a systematic review and individual patient data meta-analysis to investigate the efficacy and tolerability of different primaquine dosing regimens to prevent P vivax recurrence. Methods: For this systematic review and individual patient data meta-analysis, we searched MEDLINE, Web of Science, Embase, and Cochrane Central for prospective clinical studies of uncomplicated P vivax from endemic countries published between Jan 1, 2000, and June 8, 2023. We included studies if they had active follow-up of at least 28 days, and if they included a treatment group with daily primaquine given over multiple days, where primaquine was commenced within 7 days of schizontocidal treatment and was given alone or coadministered with chloroquine or one of four artemisinin-based combination therapies (ie, artemether–lumefantrine, artesunate–mefloquine, artesunate–amodiaquine, or dihydroartemisinin–piperaquine). We excluded studies if they were on prevention, prophylaxis, or patients with severe malaria, or if data were extracted retrospectively from medical records outside of a planned trial. For the meta-analysis, we contacted the investigators of eligible trials to request individual patient data and we then pooled data that were made available by Aug 23, 2021. We assessed the effects of total dose and duration of primaquine regimens on the rate of first P vivax recurrence between day 7 and day 180 by Cox's proportional hazards regression (efficacy analysis). The effect of primaquine daily dose on gastrointestinal symptoms on days 5–7 was assessed by modified Poisson regression (tolerability analysis). The study was registered with PROSPERO, CRD42019154470. Findings: Of 226 identified studies, 23 studies with patient-level data from 6879 patients from 16 countries were included in the efficacy analysis. At day 180, the risk of recurrence was 51·0% (95% CI 48·2–53·9) in 1470 patients treated without primaquine, 19·3% (16·9–21·9) in 2569 patients treated with a low total dose of primaquine (approximately 3·5 mg/kg), and 8·1% (7·0–9·4) in 2811 patients treated with a high total dose of primaquine (approximately 7 mg/kg), regardless of primaquine treatment duration. Compared with treatment without primaquine, the rate of P vivax recurrence was lower after treatment with low-dose primaquine (adjusted hazard ratio 0·21, 95% CI 0·17–0·27; p<0·0001) and high-dose primaquine (0·10, 0·08–0·12; p<0·0001). High-dose primaquine had greater efficacy than low-dose primaquine in regions with high and low relapse periodicity (ie, the time from initial infection to vivax relapse). 16 studies with patient-level data from 5609 patients from ten countries were included in the tolerability analysis. Gastrointestinal symptoms on days 5–7 were reported by 4·0% (95% CI 0·0–8·7) of 893 patients treated without primaquine, 6·2% (0·5–12·0) of 737 patients treated with a low daily dose of primaquine (approximately 0·25 mg/kg per day), 5·9% (1·8–10·1) of 1123 patients treated with an intermediate daily dose (approximately 0·5 mg/kg per day) and 10·9% (5·7–16·1) of 1178 patients treated with a high daily dose (approximately 1 mg/kg per day). 20 of 23 studies included in the efficacy analysis and 15 of 16 in the tolerability analysis had a low or unclear risk of bias. Interpretation: Increasing the total dose of primaquine from 3·5 mg/kg to 7 mg/kg can reduce P vivax recurrences by more than 50% in most endemic regions, with a small associated increase in gastrointestinal symptoms. Funding: Australian National Health and Medical Research Council, Bill & Melinda Gates Foundation, and Medicines for Malaria Venture. © 2024 The Author(s). Published by Elsevier Ltd. This is an Open Access article under the CC BY 4.0 license
Antimalarials; Artemether; Artemether, Lumefantrine Drug Combination; Artesunate; Australia; Humans; Malaria; Malaria, Vivax; Plasmodium vivax; Primaquine; Prospective Studies; Recurrence; Retrospective Studies; amodiaquine plus artesunate; artemether plus benflumetol; artemisinin; artesunate; chloroquine; dihydroartemisinin plus piperaquine; mefloquine; primaquine; antimalarial agent; artemether; artesunate; primaquine; abdominal pain; adult; anorexia; Article; controlled study; diarrhea; directed acyclic graph; dizziness; drug megadose; drug tolerability; female; follow up; gastrointestinal symptom; human; incidence; low drug dose; male; meta analysis; patient coding; Plasmodium vivax; Plasmodium vivax malaria; prospective study; recurrent disease; risk assessment; risk factor; systemati
NJW, (089179); Shoklo Malaria Research Unit, (220211); Centers for Disease Control and Prevention, CDC; Bill and Melinda Gates Foundation, BMGF; Wellcome Trust, WT; National Health and Medical Research Council, NHMRC, (1194702, 1196068, 2008501, 2016792, 2017436); Conselho Nacional de Desenvolvimento Científico e Tecnológico, CNPq, (223253/Z/21/Z); Capability Systems Centre, CSC
Funding text 1: RJC, BEB, MJG, JAS, and RNP are supported by Australian National Health and Medical Research Council (NHMRC) Investigator Grants (1194702, 2016792, 2017436, 1196068, and 2008501, respectively). CSC and the Shoklo Malaria Research Unit (grant 220211), and CSC, NJW, and FN (grant 089179) are supported by the Wellcome Trust. JH receives salary support from the US President's Malaria I
Elsevier Ltd
14733099
37748496
Article
Q1
8140
111